VTE Prophylaxis In Cancer – Epidemiology – Mature Markets
DRG Epidemiology's coverage of venous thromboembolism prophylaxis in cancer comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the incidence of venous thromboembolism prophylaxis in cancer for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe and Japan, and 10 years for the other countries covered in this report.
DRG Epidemiology's venous thromboembolism prophylaxis in cancer forecast will answer the following questions:
Of all people with cancer, how many in each country across the world receive venous thromboembolism prophylaxis?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of venous thromboembolism prophylaxis in cancer over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following venous thromboembolism prophylaxis in cancer patient populations:
Venous Thromboembolism Prophylaxis in Cancer Drug-Treatable Prevalent Cases
Venous Thromboembolism Prophylaxis in Cancer Drug-Treatable Prevalent Cases by Cancer Type
Venous Thromboembolism Prophylaxis in Cancer Drug-Treatable Prevalent Cases by Drug Treatment
VTE Prophylaxis In Cancer - Epidemiology - Mature Markets
Introduction
Key Findings
Prevalence of Venous Thromboembolism Prophylaxis-Eligible Colorectal Cancer per 100,000 People of All Ages in 2021 and 2041
Relative Sizes of the Factors Contributing to the Trend in Venous Thromboembolism-Eligible Colorectal Cancer Cases Over the Next 20 Years
Number of Venous Thromboembolism Prophylaxis-Eligible Colorectal Cancer Cases Prevented in the Countries Under Study as a Result of Declining Trends in Colorectal Cancer Prevalence
Epidemiology Data
Methods
Diagnosed Prevalence of Cancer Patients Eligible for Venous Thromboembolism Prophylaxis
Reference Materials
Risk/Protective Factors
Risk / Protective Factors for Venous Thromboembolism Prophylaxis in Cancer
Bibliography
Abbreviations
Glossary
Sunali D. Goonesekera, S.M.
Sunali Goonesekera, S.M., is a senior epidemiologist at Clarivate. Previously, Ms. Goonesekera conducted epidemiological research on racial/ethnic disparities in metabolic diseases at the New England Research Institute and lead-authored two manuscripts. She has contributed to multiple publications in peer-reviewed journals in epidemiology and the biological sciences. She holds a master’s degree in epidemiology from the Harvard School of Public Health and a B.A. in biology (Honors) from Dartmouth College.
